CN117750958A - 治疗间质性膀胱炎/膀胱疼痛综合征的方法 - Google Patents

治疗间质性膀胱炎/膀胱疼痛综合征的方法 Download PDF

Info

Publication number
CN117750958A
CN117750958A CN202280035703.0A CN202280035703A CN117750958A CN 117750958 A CN117750958 A CN 117750958A CN 202280035703 A CN202280035703 A CN 202280035703A CN 117750958 A CN117750958 A CN 117750958A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280035703.0A
Other languages
English (en)
Chinese (zh)
Inventor
加思·怀特赛德
斯蒂芬·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of CN117750958A publication Critical patent/CN117750958A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280035703.0A 2021-05-21 2022-05-20 治疗间质性膀胱炎/膀胱疼痛综合征的方法 Pending CN117750958A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163191536P 2021-05-21 2021-05-21
US63/191,536 2021-05-21
PCT/US2022/030400 WO2022246298A1 (en) 2021-05-21 2022-05-20 Methods of treating interstitial cystitis/bladder pain syndrome

Publications (1)

Publication Number Publication Date
CN117750958A true CN117750958A (zh) 2024-03-22

Family

ID=84140895

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280035703.0A Pending CN117750958A (zh) 2021-05-21 2022-05-20 治疗间质性膀胱炎/膀胱疼痛综合征的方法

Country Status (11)

Country Link
US (1) US20240269133A1 (https=)
EP (1) EP4340837A4 (https=)
JP (1) JP2024518804A (https=)
KR (1) KR20240012516A (https=)
CN (1) CN117750958A (https=)
AU (1) AU2022276010A1 (https=)
BR (1) BR112023023702A2 (https=)
CA (1) CA3219412A1 (https=)
IL (1) IL308315A (https=)
MX (1) MX2023013514A (https=)
WO (1) WO2022246298A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250026332A (ko) * 2022-06-24 2025-02-25 퍼듀 퍼머 엘피 과민성 방광 증후군의 치료 또는 예방 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6572891B1 (en) 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
JP4739217B2 (ja) 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
EP1676843A1 (en) 2004-12-31 2006-07-05 Nikem Research S.R.L. Substituted indole ligands for the ORL-1 receptor
WO2008033024A2 (en) 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
KR101333660B1 (ko) * 2008-07-21 2013-11-27 시오노기세이야쿠가부시키가이샤 치환-퀴녹살린-형 가교-피페리딘 화합물 및 그의 용도
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
JP7108041B2 (ja) 2018-01-24 2022-07-27 パーデュー、ファーマ、リミテッド、パートナーシップ 睡眠障害の治療及び予防
CN113301957A (zh) 2019-01-31 2021-08-24 普渡制药公司 取代的喹喔啉型桥接哌啶化合物的多晶型形式

Also Published As

Publication number Publication date
US20240269133A1 (en) 2024-08-15
EP4340837A1 (en) 2024-03-27
AU2022276010A1 (en) 2024-01-18
EP4340837A4 (en) 2025-04-09
KR20240012516A (ko) 2024-01-29
WO2022246298A1 (en) 2022-11-24
MX2023013514A (es) 2024-04-02
JP2024518804A (ja) 2024-05-02
IL308315A (en) 2024-01-01
BR112023023702A2 (pt) 2024-01-30
CA3219412A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
US9522129B2 (en) Pharmaceutical Combination
KR102061052B1 (ko) 야간 산 분비에 대한 벤즈이미다졸 유도체의 용도
JP2003523324A (ja) 組合せ医薬および胃腸疾患の処置へのそれらの使用
US20250099468A1 (en) Treating liver disorders with an ssao inhibitor
EP2666773B1 (en) Organic amine salts of azilsartan, preparation method and use thereof
US20180147169A1 (en) Pharmaceutical compositions and the treatment of overactive bladder
JP2002500651A (ja) 精神分裂病及び精神病の治療方法
CN117750958A (zh) 治疗间质性膀胱炎/膀胱疼痛综合征的方法
KR20150020160A (ko) 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
CN111658641A (zh) 慢性肾病的发展抑制或改善剂
RU2671575C2 (ru) Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
AU2004285394B2 (en) Imidazo (1,2-A) pyridine derivatives for the treatment of silent gastro-esophageal reflux
CN106061940A (zh) 治疗糖尿病和由其引发的并发疾病的化合物
US9687457B2 (en) Detrusor hyperactivity with impaired contractility ameliorating agent
US20100247584A1 (en) Compositions useful for treating gastroesophageal reflux disease
US20250381180A1 (en) Methods of treating or preventing overactive bladder syndrome
RU2361581C2 (ru) Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
TWI676477B (zh) 苯并咪唑衍生物用於夜間酸突破的用途
JP2003533482A (ja) 機能性消化不良の治療方法
KR20250099240A (ko) 간질성 폐 질환 치료를 위한 n-피리디닐 아세트아미드 유도체의 경구 제형

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination